Novel Alzheimer's medication: US panel of experts approves Donanemab's FDA approval

A committee of independent experts to the US Food and medicine Administration (FDA) decided unanimously that the benefits of the novel Alzheimer's medicine, donanemab, exceed the dangers following lengthy discussion on the cost-benefit analysis and whether the drug was worth giving given its limited benefits and adverse effects.

Eli Lilly's medication, which reduced the disease's early stages of cognitive deterioration in patients, caused a great deal of enthusiasm. However, the FDA denied permission in March because to the limited effects and potential concerns such brain hemorrhage and edema. At that point, it had stated that an independent advisory committee would need to review it. That council has now determined that, in the case of Alzheimer's, even a small